LFVNMEDIUM SIGNALOPERATIONAL10-K

LifeVantage substantially increased R&D investment while launching its new MindBody GLP-1 System product line, signaling aggressive innovation push into the weight management market.

The company's doubling of R&D spending coincides with the launch of their patent-pending GLP-1 hormone support system, indicating strategic investment in higher-growth wellness categories. This product expansion into appetite regulation represents a notable pivot from their traditional antioxidant supplements toward trending metabolic health solutions, potentially opening new market opportunities but requiring execution risk assessment.

Comparing 2025-09-04 vs 2024-08-28View on EDGAR →
FINANCIAL ANALYSIS

The balance sheet strengthened notably with current assets growing 35% and stockholders' equity up 33%, while inventory increased 37% likely supporting new product launches. Cash flow showed reduced shareholder returns with dividends declining 70% and share buybacks cut by half, suggesting management is prioritizing reinvestment over distributions. The overall picture reflects a growth reinvestment phase with improved liquidity but more conservative capital allocation to shareholders.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+100%
$700K→$1.4M

R&D investment increased 100% — signals commitment to future product development, though near-term margin impact.

Dividends Paid
Cash Flow
-70.2%
$6.9M→$2.1M

Dividends cut 70.2% — significant signal of cash flow stress or capital reallocation priorities.

Share Buybacks
Cash Flow
-51.1%
$6.4M→$3.1M

Buyback activity reduced 51.1% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-38.9%
$2.2M→$1.4M

Capex reduced 38.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+37.3%
$15.1M→$20.7M

Inventory surged 37.3% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+35.2%
$37.6M→$50.9M

Current assets grew 35.2% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+33.3%
$26.0M→$34.6M

Equity base grew 33.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+22%
$22.3M→$27.2M

Current liabilities rose 22% — increased short-term obligations, watch current ratio.

Cash & Equivalents
Balance Sheet
+19.6%
$16.9M→$20.2M

Cash grew 19.6% — improving liquidity position supports investment and shareholder returns.

Total Assets
Balance Sheet
+19.3%
$60.3M→$72.0M

Asset base grew 19.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-09-04
PRIOR — 2024-08-28
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Exhibits, Financial Statement Schedules 57 Signatures 60 5 PART I ITEM 1 BUSINESS Overview LifeVantage Corporation (the Company, LifeVantage, we, us, or our ) is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics.
Our product lines include: Protandim , our flagship line of scientifically validated dietary supplements; LifeVantage , our line of dietary supplements that include the MindBody GLP-1 System , Omega+, ProBio, IC Bright , the Rise AM Reset PM System , D3+, and Daily Wellness; PhysIQ , our Fat Burn and Prebiotic dietary supplements; TrueScience , our line of skin and hair care products and Liquid Collagen; Petandim , our companion pet supplement formulated to combat oxidative stress in dogs; and AXIO , our nootropic energy drink mixes.
Fiscal Year 2025 Highlights New Product Offerings In fiscal year 2025, we launched the next evolution in activation, the patent-pending MindBody GLP-1 System consisting of MB Core and MB Enhance .
+7 more — sign up free →
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Exhibits, Financial Statement Schedules 56 Signatures 59 5 PART I ITEM 1 BUSINESS Overview LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products.
Our line of scientifically validated dietary supplements includes our flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright , Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements.
TrueScience is our line of skin and hair care products and Liquid Collagen.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →